secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001104659-24-030475
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata secures $35M secured term loan from Innoviva at 14% interest, maturity June 2025
--------------------------------------------------------------------------------

- $35M loan from Innoviva Strategic Opportunities (Innoviva wholly-owned subsidiary, Armata's largest shareholder).
- Interest rate 14.0% per annum, secured by substantially all company assets; maturity June 4, 2025.
- Proceeds to fund Phase 2 trials of phage candidates AP-PA02 (Pseudomonas) and AP-SA02 (Staph aureus) and prepare for pivotal trials.
- Amendments to July 2023 and January 2023 credit agreements with Innoviva to conform permitted debt and lien terms.
- Loan guaranteed by domestic subsidiaries; customary affirmative/negative covenants and events of default.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/0001104659-24-030475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465924030475/tm247888d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer